We have employed whole genome microarray expression profiling as a discovery platform to identify genes with the potential to distinguish CB-MDSCs treated with or without combined cytokines, and CB-MD
To further development of our gene expression approach to chemotherapy resistance, we have employed whole genome microarray expression profiling as a discovery platform to identify genes implicated in
a Pathway gene signatures were defined as all genes up or downregulated ≥ 2-fold across all 12 and 24 h time points, relative to untreated controls. b IDs for PDGF, TGFβ, S1P, IL-13, IL-4, and RZN den